PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review

Published:2020-06 Issue:6 Volume:40 Page:3055-3063
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

MACHADO CAIO BEZERRA,DA SILVA EMERSON LUCENA,DE MORAES FILHO MANOEL ODORICO,DE MORAES MARIA ELISABETE AMARAL,MOREIRA-NUNES CAROLINE AQUINO

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance;EMBO Molecular Medicine;2023-01-18

2. Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution;International Journal of Molecular Sciences;2022-03-30

3. Cytotoxic Marine Alkaloid 3,10-Dibromofascaplysin Induces Apoptosis and Synergizes with Cytarabine Resulting in Leukemia Cell Death;Marine Drugs;2021-08-27

4. Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma;Biomedicines;2021-07-02

5. PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology;Anticancer Research;2021-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP